FOLD

Amicus Therapeut

• NASDAQ·03/27 15:30

  Why Is Adma Biologics (ADMA) Down 45.4% Since Last Earnings Report?

• TipRanks·03/11 10:36

  BioMarin price target lowered to $85 from $97 at BofA

• Reuters·03/05 00:55

  Amicus Therapeutics President and CEO Bradley L Campbell Disposes of Common Shares

• Reuters·03/03 21:55

  Amicus Therapeutics Inc. Held Special Stockholder Meeting

• TipRanks·03/03 21:34

  Amicus Stockholders Approve BioMarin Acquisition at Special Meeting

• Benzinga·03/02 11:10

  BioMarin Strengthens PKU Portfolio With FDA Approval For Younger Patients

• TipRanks·02/26 13:52

  BioMarin price target raised to $104 from $98 at Canaccord

• TipRanks·02/25 11:56

  BioMarin price target lowered to $86 from $106 at Guggenheim

• TipRanks·02/24 12:55

  BioMarin price target lowered to $95 from $98 at Oppenheimer

• Reuters·02/23 21:08

  BioMarin Q4 net income swings to a GAAP net loss of USD 47 million on 17% revenue growth to USD 875 million

• TipRanks·02/23 10:45

  Maintaining a Hold: Solid Execution at Amicus but Limited Upside Ahead of the BioMarin Acquisition

• NASDAQ·02/23 06:36

  Amicus Therapeutics Q4 Revenue Climbs

• TipRanks·02/22 06:05

  Legal Challenges Loom Over Amicus–BioMarin Merger, Raising Execution and Shareholder Risks

• Reuters·02/20 21:10

  Amicus Q4 revenue beats estimates

• Seeking Alpha·02/20 21:10

  Amicus Therapeutics Non-GAAP EPS of $0.31, revenue of $634M